Some nut job here is giving me thumbs down on every post for simply posting positive facts re DRTX.
Probably following me from some other Board...LOL! This world has gone nuts. Hope this guy doesn't
drive a car or have a gun permit! Too many nuts out there already. If you're reading this nut job, get
some help, and soon!
Drod....ML says NFLX is worth $158....Has an underperform rating (3) Sell...Ditto S&P has a Sell, and so
does Morningstar. They're having a ball with the shorts though forcing them to cover. It's a game
of last man standing it seems........
LOL.... Some of these people here have no sense of humor. If you held this stock from $16 to under $3 like some here probably have, you'd have to at least laugh at the situation somewhat. I mean we're currently in select company now Drod...You and I and all the insiders at Siga are the only ones with profits! LOL!
Who gave me two thumbs down just because I am the only one on this Board who has an actual
"profit" in Siga? I thought all my friends here would be happy for me, but oh no! Bad karma wishing
someone ill will. "Can't we all just get along?" (Rodney King)....
Up now .08 and almost $1,200...Unreal. If I do this every trading day for the next 260 trading days I'll be up approx.$312,000 on Siga this time next year!!! You talk about a winner! GLTAL's.....
$12.30 up 6%.... Need to get it over the old high of $12.96. Or, just wait for $14-$16 sometime next year and forget about the stock for now. Long huge from $7.15 and holding all. GLTAL's
Mo....I looked at THLD and my general thoughts are as follows:
1. Their competing against CELG and CELG's results in the same indication were pretty bad only providing a 2.8 month survival benefit. THLD's Phase II results for the same indication were something like 1.7 months.
Neither impressive nor probably statistically significant.
2. I don't like combo trials to begin with. Too easy for the non SOC drug to be lost in the results and
not to provide meaningful benefits.
3. Pancreatic cancer is very difficult to treat and show stat significant benefits. Especially in a combo
therapy where the SOC drug is already a known quantity.
4. Seems they've already given away alot of the potential in their first drug to MRK for milestone payments
upwards of 550 million. Problem is milestone payments usually get eaten up in general overhead over time
and really never float down to the bottom line. With MRK deeply involved takeover by someone else seems
doubtful even with good results.
5. Seems like the stock has 100% of the potential downside and only so much of the upside.
Still may need to raise cash. At this juncture too risky for me. Would rather pay $8-$10 for the
stock on some very positive results rather than $4.50 and watch it go to near zero on a failed trial.
Thanks for thinking of me. Good luck on it and others that you may be in!
Yes....SRPT thanks Mush....In from $12.98 on the major sell off day a month or so ago, and yes...Been a homerun year in the bios for me and hopefully for you and others as well. Didn't want to mention it here as some get upset. BUT...speaking of bio homeruns this year.....RLYP...12 to 24 and my single largest holding.....XOMA....$4.17 and sold at $6.12.....TTPH...$9.75 to $12....DRTX from $7.15 to $12......
One loser....ONTX...now $14.80..... Yes...thanks, and will check out THLD!
Now everyone here....Call me a liar...LOL! Too much fun. That's why I HAD to buy
15k shares of this POS at $2.92 just for posting standing on this Board. Love it here!
This POS is not down just on the fact that some lightweight CTO guy is leaving....The rumor is the CEO from Fusion who makes all the money is going to leave...or get fired....one or the other....
You need to get some help evenu2arestupidasheet...Seriously. You sound paranoid and psycho, but I'm pretty sure you know that already. Please take your lithium pills....Carrie does it on Homeland and she's a lot better now. Whatever you do...don't try and drive a motor vehicle! You can do it. Just get the help.
AK...With all due respect to your wife, who has probably forgotten more about drugs than I'll ever know,
my suggestion would be to get ahold of the MS Report on RLYP...the one with the $57 price target...then
the Cowen...Wedbush... and.Stifel reports as well, and see if there might be a common theme in those four reports. Of course the GP is going to say "change your diet" and get more exercise for CKD patients...along perhaps with lose some weight comments... You tell me how that's worked in modern America so far with our obese population.
Now after doing all of the above, and before the patient leaves, the GP is just going to mention the newly FDA approved little pill that should "help" them in their task. Just in case the patient happens not to watch their diet
or get more exercise. And the 10 million patients I referenced that could benefit from the drug. Actually understated to some extent.
But what you may be really missing here are the players involved with this company. Been there done this quite a few times. IMHO this one is bought out within six months following FDA approval. Mid 50's.
Ditto with DRTX following approval.... $16-$19. The stars are all aligned on both of these. Doctors need more weapons, and RLYP is it for hyperkalemia.
But I did sell 50% today at $24.30 avg. so the position I now hold is not only "free" but I have already banked a nice profit to boot! Your post the other day reminded me not to be too greedy so thanks my man!
What the VC's and Founder should do is make a tender offer for the stock at or near the IPO price, and take it back private again. Would get rid of all the lawsuits and let them do with the company as they see fit.
Drod...I'm only playing it for a bounce. If a company has only one contract....only one product....no pipeline and R&D is basically being wound down to nothing.....and another company has a judgment against the company based on that one product....Not sure how bright the future could be.
Just hoping that at a 173 mil market cap that the remaining part of the BARDA contract justifies a higher valuation and we rally back to $3.60 in the next few months.
A publication titled "Business Insider" just reported that VMEM CTO Jonathan Goldrick has just left the company "on good terms" and his responsibilities are being shared by CTO & Founder Jon Bennett and CTO Som Sikdar".
"Rumors have been circulatiing that CEO Don Basile could leave soon as well.". A VMEM's spokesperson apparently replied that they do not comment on rumors.
The good news just keeps rolling in.....
Y E S....Drod is the winner !! But hey...don't pick on me...I said in my post today that I thought
your $2.90 post "pre-dated my post of 12/4 by months or even years"! LOL!
OK...The great debate continues..... I have a post on 12/4/2013 that says "Buy at $2.90"...In fact the post is titled that. Jay....When did you first post to buy at $2.90? I do think Drod pre-dates my post to buy in the $2.90's by months, or perhaps, even years now...LOL!
Look....For all of our sakes, and our children's sake, I for one certainly hope that Ibrutinib comes even close to the holy grail cure for certain forms of cancer. With that said, I think the FDA will require a much larger Phase II/III confirmatory trial prior to approving the drug. I realize I might be in the minority, here but there is far too much at stake not to see how the SAE's pan out in a much larger trial of say 500-1000 patients. I mean 43% AE's in CLL patients going into year one of treatment is a pretty startling statistic, even though it did drop very meaningfully by year two.
If you think about it, how can you prescribe it to some very sick patients knowing that 43% are going to suffer some form of adverse event during the first year of treatment from the not so serious, to the very serious?
And what were the CR statistics within the CLL group?